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ABSTRACT
Backround and aims: Having entered the recent public and research zeitgeist, microdosing involves
consuming sub-perceptual doses of psychedelic drugs, allegedly to enhance performance, creativity,
and wellbeing. The results of research to date have been mixed. Whereas most studies have reported
positive impacts of microdosing, some microdosers have also reported adverse effects. In addition,
research to date has revealed inconsistent patterns of change in personality traits. This prospective
study explored the relationship between microdosing, personality change, and emotional awareness.
Methods: Measures of personality and alexithymia were collected at two time points. 76 microdosers
participated at baseline. Invitations to a follow-up survey were sent out after 31 days, and 24 participants were retained. Results: Conscientiousness increased, while neuroticism decreased across
these time points (n 5 24). At baseline (N 5 76), neuroticism was associated with alexithymia. In
addition, neuroticism correlated negatively with duration of prior microdosing experience, and extraversion correlated positively with both duration of prior microdosing experience and lifetime
number of microdoses. Conclusion: These results suggest that microdosing might have an impact on
otherwise stable personality traits.
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There has been recent growing public awareness about the phenomenon of “microdosing”,
with stories featured in Vogue (Mechling, 2017), Forbes (Williams, 2017), The New York
Times (Glatter, 2015) and the Australian Financial Review (Valentish, 2018). Microdosing
involves taking small quantities of psychedelic substances at regular or semi-regular intervals
with the intention to improve psychological wellbeing, work performance and/or creativity
(Fadiman, 2011). Classic psychedelic substances, such as lysergic acid diethylamide (LSD),
psilocybin and mescaline, act (at least partially) by binding to the 2A subtype of 5-hydroxytryptamine receptors in the brain where they act as agonists (Nichols, 2016). Consumption of recreational doses of psychedelic substances is usually associated with an
alteration of consciousness. Such consumption often leads to changes in visual and auditory
perception. Microdoses are considered subperceptual doses, usually ranging from 1/20 to 1/
10 of a recreational, psychoactive dose (Kuypers et al., 2019). Ideally, such subperceptual
doses should not result in visual effects (Fadiman, 2011) or a marked change in consciousness
(Johnstad, 2018).
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LSD and psilocybin are the most common psychedelics
reportedly microdosed (Anderson et al., 2019), so a typical
microdose might be considered between 4 and 20 mg of LSD
or between 0.1 and 0.6 g of dried psilocybin mushrooms (Lea,
Amada, & Jungaberle, 2019). According to microdosers’ selfreports, there is individual variance in the optimal dose
required to obtain the intended effects while remaining
subperceptual (Hupli, Berning, Zhuparris, & Fadiman, 2019).
Most microdosers reportedly adjust their initial dose through
trial and error (Lea et al., 2019). While various microdosing
regimens have been identiﬁed by Lea, Amada, Jungaberle,
Schecke and Klein (2020), most people reported microdosing
between once and a few times a week, usually in the morning
and as a cyclic activity (e.g., every third day). According to
Johnstad (2018), most experienced microdosers restricted
their use to phases lasting from a few weeks to a few months,
as some users believe that microdoses may not provide
beneﬁts when used for long durations.
Although acute effects of microdosing have been found
to be subtle in clinical trials (Bershad, Schepers, Bremmer,
Lee, & Wit, 2019; Ramaekers et al., 2020; Yanakieva et al.,
2018), proponents claim that regular microdosing can lead
to a range of long-term beneﬁts, such as improved mood,
wellbeing, sociability, creativity and performance (Webb,
Copes, & Hendricks, 2019). Andersson and Kjellgren’s
(2019) thematic analysis of 32 microdosing videos on the
Youtube platform aimed to understand microdosers’ experiences, expectations, approaches, and viewpoints. They found
claims that microdosing led to a facilitation of self-reﬂection
and personal insights. Meanwhile, people who engage in
microdosing primarily to address an existing mental health
issue have reported they do it to self-treat depression, (social)
anxiety, suicidality, addiction, trauma, intrusive thoughts, and
chronic pain (Petranker, Kim, & Anderson, 2020).
Although psychedelic microdosing has been growing in
popularity (Anderson et al., 2019; Hupli et al., 2019), Fadiman (2011) acknowledged that the practice likely has roots
going back to indigenous cultures and healers who likely
“systematically and fully explored every dose level” (p. 210).
He further recognized that modern psychedelic research had
often overlooked these subperceptual doses.
Following a 30-year embargo on psychedelic research
(Strauss, Bright, & Williams, 2016), there has been a recent
resurgence of scientiﬁc interest in the therapeutic and medicinal effects of psychedelic substances, often referred to as
the psychedelic renaissance (Bright & Williams, 2018).
Contemporary clinical research on higher doses of psychedelics has shown that LSD administered in a supportive
setting increases optimism in healthy subjects (CarhartHarris et al., 2016). High doses of psilocybin decreased
depressive and anxious symptoms in patients with lifethreatening cancer diagnoses (Grifﬁths et al., 2016) and
promoted abstinence in patients with alcohol (Bogenschutz
et al., 2015) and tobacco addiction (Garcia-Romeu, Johnson,
& Grifﬁths, 2014). However, contemporary microdosing
research remains limited.
To date, few placebo-controlled, randomized, doubleblind studies have investigated the effects of microdosing
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LSD on mood, perception and cognition. Yanakieva et al.
(2018) observed changes in time perception following LSD
microdosing. Bershad et al. (2019) observed a dose-related
subjective sensitivity to drug effects, and an increase in
ratings of vigor at 26 mg of LSD. Ramaekers et al. (2020)
observed a signiﬁcant increase in pain tolerance and
decreased pain perception, which was signiﬁcant at doses of
20 mg of LSD. Family et al. (2020) found no adverse effects
from 5 to 20 mg LSD but no marked cognitive changes. In
contrast, Hutten et al. (2020) found that low doses of LSD
(5–20 mg) increased positive mood, friendliness, arousal, and
decreased attentional lapses. However, increases in anxiety
and confusion were also observed. Finally, Holze et al.
(2020) found that the threshold-dose for subjective drug
effects was at 10 mg of LSD.
A non-blinded experimental study by Prochazkova et al.
(2018) examined the cognitive-enhancing potential of
microdosing psilocybin-containing trufﬂes in a naturalistic
setting. Microdosers were found to have signiﬁcantly
increased performance in convergent and divergent thinking
after a non-blinded microdose.

Microdosing and personality
Polito and Stevenson (2019) were the ﬁrst researchers to
systematically investigate the long-term effects of microdosing psychedelics by tracking the experiences of microdosers (N 5 63) over a six-week period. Participants ﬁlled out
daily reports and completed a comprehensive questionnaire
battery at baseline and the end of the study. The results of this
prospective study suggested that microdosing led to improved
mental health (decreased depression and stress) and to
improved attentional capacities (decreased mind wandering
and increased levels of absorption). In addition, a small but
signiﬁcant increase of the personality trait neuroticism was
observed. Neuroticism is a person’s tendency to experience
negative emotions more easily and has been described as
emotional instability. Personality traits such as neuroticism
are considered relatively stable constructs and typically not
expected to alter over a short period of time. Differences in
personality between microdosers and controls have also been
found in the trait openness; however, to date this has only
been reported in cross-sectional designs, so it is unclear if
microdosing is the cause of these differences (Anderson et al.,
2019; Bright, Gringart, Blatchford, & Bettinson, 2021).
The increase in the personality trait neuroticism
observed by Polito and Stevenson (2019) appears to
contradict the ﬁnding that people who microdose tend to
have improved mental health, observed by Polito and Stevenson and others (Anderson et al., 2019; Fadiman, 2011;
Webb et al., 2019). However, Bright et al. (2021) found that
microdosers had higher levels of depression and anxiety
compared to a yoga control group. In a recent review of 14
microdosing studies, Kuypers (2020) observed that “while
low LSD doses were experienced as pleasant, it was also
shown that drug disliking and anxiety increased, and that a
cycling pattern of depressive and euphoric mood changes
can occur” (Kuypers, 2020, pp. 9–10). Andersson and
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Kjellgren (2019) observed increased negative emotion
among microdosers, proposing increased emotional awareness may initially trigger negative emotions, but also provide
“more insights and possibilities to work through personal
issues” (Unwanted effects and lack of results, para. 2).
Similarly, Polito and Stevenson (2019) suggested that
reduced mind wandering and increased absorption in immediate experiences might assist participants to identify and
process both negative and positive emotions, leading to
more emotionally intense experiences.
Our study aimed to further understand the relationship
between microdosing, changes in personality over time and
emotional awareness. Personality can be assessed by using
the five-factor model of personality, where each of the factors
(extraversion, agreeableness, conscientiousness, neuroticism
and openness) represents a distinct personality trait (Costa &
McCrae, 1992). Extraversion describes the sociability of an
individual. An extroverted person might be more talkative in
social settings or get excited more easily. Agreeableness reﬂects the degree to which a person may be altruistic, cooperative and trust others. Conscientiousness represents the
determination and self-control of an individual. Individuals
who score high on this scale are typically considered reliable,
responsible and organized. Openness reﬂects someone’s interest in new experiences and impressions.
Although not a classic personality trait, another individual difference characteristic that may shape the experience of microdosers is alexithymia. Alexithymia represents a
person’s emotional literacy and is an indicator of emotional
insight. In particular, alexithymia reﬂects a difﬁculty in
identifying, describing and expressing one’s feelings (Bagby,
Parker, & Taylor, 1994).

Research questions
1. Does microdosing lead to changes in self-reported personality traits?
2. Is an individual’s level of prior microdosing experience
related to self-reported personality traits?
3. Are emotional insight and neuroticism associated in
people who microdose?
4. Does emotional insight predict further increases in
neuroticism among people who microdose?

METHODS
Data were collected at two time points using a prospective
within-subject design. There was a minimum interval of 31
days between Time 1 (T1) and Time 2 (T2) to ensure that
self-reported microdosers would be able to have multiple
dosing sessions between the time points.

Participants
Participants were recruited through announcements on
webpages, newsletters and the social media of non-profit

psychedelic organizations (e.g. PRISM Australia, the MIND
Foundation, the OPEN Foundation, the Third Wave,
microdosing.nl). Additional recruiting strategies included
posts in psychedelic Facebook groups and online discussion
forums (e.g., the microdosing subreddit on reddit.com).
Recruitment occurred between October 2019 and April
2020. Participants were asked to only participate if they were 18
years or older, fluent in English, and had past and current
experience with microdosing. Participants with a current mental
health or neurological diagnosis, a current substance use disorder or a history of psychosis were asked to not participate.
Ninety participants submitted complete responses at
T1. After a minimum waiting period of 31 days, 32 participants responded to an invitation to complete the followup survey at T2, of which 28 participants submitted complete responses. Participants were excluded from the
analysis if they: were not current microdosers (n 5 4);
microdosed a substance not considered a psychedelic (n 5
2); reported dosing amounts typically considered a recreational dose (e.g., 75-100 mcg of LSD [n 5 5]); reported
very high (non-psychedelic) drug use (n 5 5). Finally, one
participant reported using medication for depression during the course of the study and was excluded. Exclusion of
these participants led to 76 responses for T1 and 24 responses for T1 and T2.
Participants (N 5 76) were aged between 18 and 68 years
(M 5 33.0 years; SD 5 13.1). 61 participants were male
(80.3%), 14 were female (18.4%) and 1 (1.3%) self-classiﬁed
as “Other”. Participants reported residing in North America
(50%), Europe (34.2%), Australia or New Zealand (10.5%),
Asia (2.6%), South Africa (1.3%), and Central America
(1.3%). Participants who completed both parts of the survey
(n 5 24) were also aged 18–68 years (M 5 33.3 years; SD 5
11.8). The ratio between males (79.2%) and females (20.8%)
was similar to the T1 sample, and participants reported
residing in similar countries.

Procedure
Potential participants were directed to the study webpage,
hosted on the Qualtrics platform. Participants who chose to
begin the survey were asked to create an anonymous e-mail
address. Instructions explaining how to do this were provided. To secure participants’ anonymity, they were asked to
use an unidentiﬁable name. Participants then completed the
online survey at T1, which included: the completion of the
substance use disorder screening tool ‘Modiﬁed ASSIST’; the
M5-50 Personality Questionnaire; and the 20-Item Toronto
Alexithymia Scale (TAS-20). Participants also provided basic
demographic information and answered questions about
their microdosing behavior (e.g., type of substance
consumed; primary motivation for microdosing).
31 days after survey completion, an invitation link to a
follow-up survey was sent to the anonymous e-mail addresses of participants. Participants who did not respond to
the follow-up survey at T2 were sent a second reminder after
another 14 days. The M5-50 Personality Questionnaire and
TAS-20 were re-administered at T2.
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The surveys took about 15 minutes to complete and there
was no incentive for participation. Ethical approval was
provided by the Ethics Committee of the Georg-Elias-M€
ullerInstitute of Psychology (Application number 2019/232).

Table 1. Substances consumed for microdosing

Materials
Modified version of the alcohol, smoking and substance
involvement screening test (World Health Organization,
2010). Developed by the World Health Organization, the
Alcohol, Smoking and Substance Involvement Screening Test
(ASSIST) was designed to detect risky and harmful substance use behavior, in addition to dependence. It is usually
administered in primary healthcare settings. The ASSIST has
demonstrated good reliability and feasibility, and good
concurrent, construct, predictive and discriminant validity
(World Health Organization, 2010). We used a modiﬁed
version of the ASSIST consisting of 7 items, which collect
information about the types of drugs ever used and their
frequency of consumption. Follow up items are asked to
assess for hazardous use, harmful use, and dependence (e.g.,
“During the past three months, how often have you failed to
do what was normally expected of you because of your use of
[ﬁrst drug, second drug, etc.]?”). The modiﬁed version asked
about the frequency of substance use within the last year and
social difﬁculties associated with substance use within the
past three months. An 8th item, concerning injected substance use, was omitted. Ratings of frequency (e.g. “Never”,
“Daily or almost daily”) were scored from 0 to 6 and an
overall score was calculated. Any participant who had used a
drug within the last three months and exceeded a total score
of 27 for that drug was excluded from the analysis due to
very high (non-psychedelic) substance use.
M5-50 Personality questionnaire (Socha, Cooper, & Mccord,
2010). The M5-50 Personality Questionnaire is a measure of
the personality domains extraversion, agreeableness, conscientiousness, neuroticism and openness to experience.
The questionnaire consists of 50 items with 10 items for
each subscale, taken from Goldberg’s International Personality Item Pool (Socha et al., 2010). The M5-50 Personality
Questionnaire was designed as a short form of Costa and
McCrae’s (1992) NEO-PI-R (Socha et al., 2010). A ﬁve-point
Likert-type scale is used to rate level of agreement with each
item, with scores ranging from 1 (Inaccurate) to 5 (Accurate). The measure has been shown to have good reliability
and a reasonably good model ﬁt (Socha et al., 2010).
20-Item toronto alexithymia scale (TAS-20; Bagby et al.,
1994). The TAS-20 is a 20-item measure of alexithymia.
Questions focus on difficulties identifying feelings, difficulties describing feelings, and externally oriented thinking.
Participants rate their level of agreement with each statement on a five-point Likert scale. The overall scale has
demonstrated good internal consistency and a good testretest reliability (Bagby et al., 1994).
During the analysis, it was discovered that due to an
administrative error, Item 2 of the TAS-20 had been phrased

Microdosing substance
Participants T1 (N 5 76)
Participants T1 and T2 (n 5 24)

Psilocybin

LSD

Other

48.7%
45.8%

36.8%
37.5%

14.5%
16.7%

incorrectly and so this item was omitted from all calculations.

RESULTS
Participants consumed between 3 and 30 microdoses during
the study period (M 5 11.3 microdoses; SD 5 7.53). As can
be seen in Table 1, the majority of participants reported
microdosing psilocybin or LSD. Speciﬁcally, 33 participants
reported microdosing with psilocybin (Dose M 5 0.367 g,
SD 5 0.503), and 23 participants reported microdosing with
LSD (Dose M 5 15.3 mg, SD 5 6.27). There were an additional 4 psilocybin microdosers and an additional 5 LSD
microdosers who did not provide clear information on their
typical dose. Finally, 11 participants reported microdosing a
range of other substances including 1P-LSD/1cP-LSD, Ibogaine, DMT, 4-HO-MET, 4-AcO-MET, ALD-52, 25-I, and
BOD. As can be seen in Table 2, the primary motives were
Personal Growth and Self Medication. A smaller number of
participants reported microdosing primarily to Increase
Productivity, Curiosity or to Increase Creativity. Speciﬁed
text-responses of participants coded as “Other”, revealed that
their motives were typically a combination of motives outlined above. As can be seen in Tables 1 and 2, participants’
reported substance and motive were relatively consistent at
T1 and T2.
Alpha was set at 0.05 for all analyses, parametric inferential statistics were used for all analyses, and assumptions
were met unless stated otherwise.
To explore whether any of the personality traits changed
over time, five two-tailed, simple paired t-tests were conducted comparing mean scores of T1 against mean scores of
T2. As can be seen in Table 3, conscientiousness signiﬁcantly
increased (n 5 24, t 5 2.26, P 5 0.034, d 5 0.460), while
neuroticism signiﬁcantly decreased (n 5 24, t 5 3.26, P 5
0.003, d 5 0.666). There was no change in extraversion,
agreeableness, or openness.
We also investigated whether prior microdosing experience (indexed by total lifetime doses, and number of months
since first microdose) correlated with any personality traits
at T1. Both indicators of prior experience were not normally
distributed in our sample, so the Spearman correlation was
used. Based on the responses of all 76 participants at T1, a
negative correlation was found between prior experience
in months and neuroticism (r 5 0.237, P 5 0.039),
though not with participants’ lifetime number of microdoses. Extraversion correlated positively with prior
experience in months (r 5 0.228, P 5 0.047) and also
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Table 2. Primary microdosing motive
Primary motive
Participants T1 (N 5 76)
Participants T1 and T2 (n 5 24)

Self-medication

Personal growth

Increase productivity

Increase creativity

Curiosity

Other

23.7%
25%

46.1%
41.7%

9.2%
12.5%

1.3%
–

3.9%
4.2%

15.8%
16.7%

Table 3. General changes in personality
Time 1

Personality trait
Agreeableness
Conscientiousness
Extraversion
Neuroticism
Openness

Time 2

M

SD

M

SD

3.73
3.45
2.95
2.69
4.13

0.504
0.647
0.828
0.954
0.459

3.89
3.67
3.18
2.13
4.20

0.295
0.600
0.711
0.502
0.402

t

P

d

1.82
2.26
2.04
3.26
1.22

0.082
0.034*
0.053
0.003**
0.236

0.371
0.460
0.415
0.666
0.249

*P < 0.05, **P < 0.01, two-tailed.

with participants’ lifetime number of microdoses (r 5
0.262, P 5 0.022).
The relationship between emotional insightfulness and
the personality trait neuroticism was explored by examining
Pearson’s correlation between alexithymia at T1 and
neuroticism at T1. There was a signiﬁcant positive association between alexithymia and neuroticism (N 5 76, r 5
0.526, P 5 <0.001). Finally, we investigated whether there
was a relationship between alexithymia at baseline and
changes in neuroticism over the course of the study using
linear regression. Alexithymia at T1 was entered as the
predictor, while the difference in neuroticism scores (Time 2
minus Time 1) was entered as the dependent variable.
Alexithymia was not a signiﬁcant predictor of the change in
neuroticism (n 5 24, P 5 0.077, R2 5 0.135). Data for this
study are available at https://osf.io/f9vr5/.

DISCUSSION
In the present study, we aimed to explore the relationship
between microdosing, changes in personality over time, and
alexithymia. After at least one month of microdosing, we
observed significant increases in conscientiousness and decreases in neuroticism. Agreeableness, extraversion and
openness were unaffected. Although alexithymia and
neuroticism were positively correlated at T1, alexithymia did
not predict neuroticism changes between T1 and T2. Extraversion was positively correlated with participants’
number of lifetime doses and the duration of their prior
microdosing experience. Neuroticism was negatively correlated with the duration of prior microdosing experience.

Microdosing and personality
Contrary to previous findings by Polito and Stevenson
(2019), we observed a signiﬁcant decrease in neuroticism.

The present ﬁnding appears more consistent with other
contemporary microdosing research (Anderson et al., 2019;
Webb et al., 2019) and many anecdotal reports highlighting
the positive effects of microdosing on mental health, mood
and (psychosocial) wellbeing (Fadiman, 2011; Waldman,
2018). Our ﬁnding is also more consistent with clinical
research on higher psychedelic doses, in which the administration of oral psilocybin (10 mg and 25 mg, one week
apart) has been linked to decreased neuroticism at a threemonth follow-up (Erritzoe et al., 2018).
One key difference between the present study and Polito
and Stevenson’s study is that the samples appear to differ in
terms of their prior microdosing experience. The majority of
Polito and Stevenson’s participants (66.7%) had microdosed
10 times or less, including a substantial portion (31.7%) who
had never microdosed before taking part in the study. By
contrast, only 37.5% of participants in the current study had
microdosed 10 times or less, and all our participants reported at least some prior microdosing experience. As previously discussed, research by Andersson and Kjellgren
(2019) suggests that microdosing may initially trigger
negative emotions, which in turn provides opportunities to
address personal issues. Polito and Stevenson’s sample
contained mainly participants who were microdosing naı€ve
when entering the study or still in an early phase of their
microdosing experience. The initial phase of microdosing
may have increased awareness of unaddressed (negative)
emotions, leading to increased scores in neuroticism. Participants in the current sample, due to relatively greater prior
exposure to microdosing, may have learned to process and
integrate their emotions better. This interpretation is supported by the negative correlation between prior microdosing experience and neuroticism at T1. Longer term
microdosing might actually reduce rather than increase
neuroticism. However, it is also possible that microdosers
who demonstrate larger decreases in neuroticism are more
likely to engage in long-term microdosing.
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Conscientiousness significantly increased in our sample,
suggesting that participants perceived themselves as more
organized, responsible and determined after microdosing.
Microdosers might be able to complete their daily tasks with
more focus, resulting in more reliable and organized
behavior. The increase in conscientiousness is consistent
with Andersson and Kjellgren’s (2019) ﬁndings, where
microdosers reported “less procrastination and a spontaneous impulse to clean the house, tidy drawers, pay bills, or
address other postponed or neglected tasks” (Insights and
transformation section, para.3). The present ﬁnding is also
consistent with research on higher psilocybin doses by
Erritzoe et al. (2018), who observed a trend toward increased
conscientiousness at a 3-month follow-up.
We observed no significant change in extraversion,
agreeableness, or openness from T1 to T2 (although there
was a trend toward increased extraversion, P 5 0.053).
Extraversion was also positively correlated with prior
microdosing experience. This suggests that extroverted
individuals may be more likely to engage in long-term
microdosing. Findings from high-dose psychedelic research
have shown that ingestion of psilocybin has led to persistent increases in openness (Erritzoe et al., 2018; Maclean,
Johnson, & Grifﬁths, 2011). Similarly, in research with
cross-sectional designs (Anderson et al., 2019; Bright et al.,
2021), microdosers have been found to score higher in
openness compared to non-microdosing controls. The null
ﬁnding related to openness in the current study suggests
that rather than microdosing increasing openness, it may
be that people already high in openness are more likely to
try microdosing.

Journal of Psychedelic Studies 5 (2021) 1, 9–16

microdosing in a naturalistic setting, this study was not as
precise as a controlled experiment with predetermined dosing
amounts, fixed schedules, and a placebo-control condition.
Participants were recruited worldwide and through a wide
range of psychedelic organizations and forums. However, the
survey was carried out in English, making it inaccessible for
non-English speaking microdosers. Due to ethical restrictions
of this study, we were not able to recruit participants with a
current mental health diagnosis or substance use disorder. This
exclusion criterion limits the generalizability of our sample.
Only 23.7% of participants selected Self-Medication as their
primary motive; the number of people engaging in microdosing with this motive is likely to be higher in the general
population. In addition, there could have been sampling bias,
leading to an over-representation of participants who had
mainly positive experiences with psychedelics. Finally, most
participants reportedly engaged at least once in recreational
drug use while microdosing (excluding alcoholic beverages and
tobacco products), making it difﬁcult to be certain that effects
found are entirely due to microdosing. Other observational
studies have also found that microdosers often report past
experience with, or recent use of, recreational drugs (Anderson
et al., 2019; Johnstad, 2018; Lea, Amada, Jungaberle, Schecke,
Scherbaum & Klein, 2020; Rosenbaum et al., 2020; Webb et al.,
2019), presenting a common limitation in studies of microdosing in naturalistic settings. For this reason, the current
ﬁndings should be interpreted with caution. Future research
could build upon our exploratory ﬁndings by testing speciﬁed
hypotheses regarding personality change in an experimental
setting with a placebo control condition. Further, it will be
important to untangle the effects of recreational psychedelic
use by including psychedelic naı€ve microdosers.

Alexithymia
Alexithymia and neuroticism were positively correlated at
T1, demonstrating that emotional insightfulness may be
associated with lower neuroticism among microdosers.
These findings are consistent with previous research that has
found relationships between neuroticism and alexithymia in
healthy Italian graduate students (Messina, Fogliani, &
Paradiso, 2010), parents of daughters with eating disorders
(Espina, 2003), and in subjects with medically unexplained
physical symptoms (Gucht, Fischler, & Heiser, 2004). These
diverse ﬁndings indicate that emotional insightfulness may
generally be associated with lower neuroticism.
In the current study alexithymia at T1 did not predict
subsequent neuroticism change. However, the negative
correlation between prior microdosing experience and
neuroticism suggests that more experienced participants
may have learned to integrate their emotional insights.

CONCLUSION
Our results indicate that microdosing may impact personality
traits. In this study a short course of microdosing led to
increased conscientiousness. Contrary to earlier findings with
mostly naı€ve participants, we also found that neuroticism
decreased in this sample of more experienced microdosers. In
addition, prior microdosing experience correlated negatively
with neuroticism and positively with extraversion. Finally, we
found a negative association between emotional insight and
neuroticism, although this was not predictive of future personality change. Future research could build upon these findings by investigating whether personality variables develop
differently between microdosing naı€ve and experienced participants. The role of alexithymia could also be explored in
microdosers with a current mental health diagnosis.

Limitations and future directions
There are several limitations to the study design. Due to
practical and legal restrictions, our study was not dose or
placebo controlled. Participants microdosed a range of substances and differed in dosing amounts and their frequency of
consumption. Although this allowed an examination of
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